MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

207.9 -1.41

Buy Sell

Overview

Share price change

24h

Current

Min

207.9

Max

212.01

Key metrics
By Trading Economics
Income	-22M -61M
Sales	56M 214M
Profit margin	-28.549
Employees	1,017
EBITDA	-56M -53M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+24.83% upside

Market Stats
By TradingEconomics
Market Cap	1B 13B
Previous open	209.31
Previous close	207.9

News Sentiment

By Acuity

50%

151 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

WiseTech to Sell Expedient to Appease Competition Regulator

30 gru 2025, 17:12 UTC

Major Market Movers

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 gru 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 gru 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 gru 2025, 20:37 UTC

Earnings

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 gru 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30 gru 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 16:20 UTC

Earnings

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 gru 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 gru 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 gru 2025, 15:10 UTC

Acquisitions, Mergers, Takeovers

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 gru 2025, 14:24 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 gru 2025, 14:22 UTC

Acquisitions, Mergers, Takeovers

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 gru 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 gru 2025, 14:17 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 gru 2025, 14:16 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 gru 2025, 14:14 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 gru 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

LVMH: Les Editions Croque Futur Is a French Publishing House

30 gru 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

LVMH Acquires Les Editions Croque Futur

30 gru 2025, 13:49 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 gru 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 gru 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 gru 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 gru 2025, 11:55 UTC

Market Talk

Earnings

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 gru 2025, 11:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 gru 2025, 11:35 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

24.83% upside

12 Months Forecast

Average 263.42 USD 24.83%

High 325 USD

Low 220 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

151 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.